

Novel Multidrug Resistance-Associated Polypeptide

Abstract of the Disclosure

Compositions and methods are disclosed for improving the effectiveness of a chemotherapeutic regimen to eradicate multidrug-resistant transformed cells from the body of a mammal, preferably from the body of a human. The present disclosure capitalizes on the discovery of a novel multidrug-resistance associated protein (MRP), herein designated MRP- β . The disclosed compositions include MRP- β nucleic acids, including probes and antisense oligonucleotides, MRP- β polypeptides and antibodies, MRP- β expressing host cells, and non-human mammals transgenic or nullizygous for MRP- β . The disclosed methods include methods for attenuating aberrant MRP- β gene expression, protein production and/or protein function. In addition, methods are disclosed for identifying and using a modulator, such as an inhibitor, of MRP- β . Preferably, the modulator is a small molecule.

404PRHW5508/03.506588-1